

Assessment of the immunogenicity and safety of the Northern Hemisphere 2009/2010-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMA) regulations

Submission date 28/04/2009	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 28/05/2009	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 28/05/2009	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Michael Seiberling

Contact details
Swiss Pharma Contract Ltd
Lettenweg 118
Allschwil
Switzerland
4123

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

INF-V-A003

Study information

Scientific Title

Study objectives

The Northern Hemisphere 2009/2010-season influenza vaccine fulfills the European Medicines Agency (EMA) requirements for re-registration of influenza vaccines.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Local Medical Ethics Committee (Ethikkommission beider Basel [EKBB]), Switzerland on the 31th March 2009 (ref: 64/09)

Study design

Open non-randomised uncontrolled safety/efficacy study

Primary study design

Interventional

Secondary study design

Other

Study setting(s)

Not specified

Study type(s)

Prevention

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Influenza

Interventions

Biological: single dose of trivalent virosomal adjuvanted influenza vaccine (Inflexal® V). Total duration of follow-up: approximately three weeks

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Trivalent virosomal adjuvanted influenza vaccine (Inflexal® V)

Primary outcome measure

Immunogenicity, assessed by haemagglutination inhibition test; blood to be collected before and approximately three weeks after vaccination.

Secondary outcome measures

Safety, assessed at baseline and at three weeks after vaccination, including a four-day adverse event questionnaire, soliciting a set of local and systemic adverse events (AEs) according to the European Medicines Agency (EMA) specifications.

Overall study start date

01/06/2009

Completion date

30/08/2009

Eligibility

Key inclusion criteria

1. Healthy female and male volunteers equal to or older than 18 years of age on the day of enrolment
2. Written informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

110

Key exclusion criteria

1. Pregnancy and lactation
2. Serious adverse reaction to any influenza vaccine

Date of first enrolment

01/06/2009

Date of final enrolment

30/08/2009

Locations

Countries of recruitment

Switzerland

Study participating centre

Swiss Pharma Contract Ltd

Allschwil

Switzerland

4123

Sponsor information

Organisation

Crucell, Berna Biotech Ltd (Switzerland)

Sponsor details

Rehhagstrasse 79

Berne

Switzerland

3018

Sponsor type

Industry

Website

<http://www.crucell.com>

Funder(s)

Funder type

Industry

Funder Name

Crucell, Berna Biotech Ltd (Switzerland)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration